Two Compounds Discovered that Pave the Way for New Class of AIDS Drug

According to the World Health Organization, about 33 million people currently live with HIV infections. Several drugs used to treat AIDS inhibit this HIV protease target, but drug-resistant mutants that impede the effectiveness of these drugs keep appearing and getting worse.

A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.

Two members of the FightAIDS@Home team, Research Associate Alex L. Perryman, Ph.D., and Professor Arthur J. Olson, were part of this innovative research and are now working to extend it. This experimental breakthrough will serve as the basis for new drug development to combat the increasing number of drug-resistant HIV strains and to improve the potency of current drug therapies. The results form the groundwork for a new class of more powerful treatments to fight HIV/AIDS. The findings appear as the March cover story in the journal Chemical Biology and Drug Design.

Utilizing computing power from 1.5 million devices networked through IBM’s World Community Grid, the new sites on the HIV protease are being used as docking targets for virtual screening experiments, in order to guide the development of these chemical compounds into a new class of potent HIV inhibitors. Using the massive computational resources of the World Community Grid, the FightAIDS@Home team has already docked over 500,000 compounds against these newly characterized binding sites.

By aggregating the unused cycle time of 1.5 million personal computers donated by volunteers in over 80 countries, World Community Grid is now the world's largest public humanitarian grid, equivalent in power to a Top 15 supercomputer, and crunched more than 107,000 years of computational time in just 5 years for the Scripps Research Institute project, providing more than 104 million calculations.

"IBM's World Community Grid and its volunteers help us run millions of computations to evaluate the potential interactions between compounds and mutant viral proteins," said Dr. Arthur J. Olson, Anderson Research Chair Professor, Department of Molecular Biology at The Scripps Research Institute. "Through this effort we were able to significantly speed up our investigation. Without the computational power of World Community Grid, it would have taken us many more years to get to this important step in our research."

Once the HIV virus enters a human cell, it uses a small set of proteins called enzymes to force the cell to produce many new copies of itself, which then go on to infect other cells. Most HIV drugs work by blocking the operation of one or more of these enzymes. In the current work, the Scripps researchers are looking for new compounds that will stabilize the inhibited conformation, or shape, of the HIV protease enzyme, and thus help stop the virus from replicating. Because HIV mutates so frequently, some drugs that inhibit the enzyme from replicating are no longer working, or are not working as effectively. By running calculations on the World Community Grid FightAIDS@Home project, the team at Scripps is trying to develop new drugs that bind to more parts of the mutant enzyme, thereby shutting it down more effectively.

World Community Grid speeds up humanitarian research by providing scientists with millions of dollars of supercomputer power, for free, that would otherwise not be available to them.

In a second paper recently published in the Journal of Molecular Biology, the Scripps team has used computational modeling to improve understanding of another HIV enzyme and key drug target - integrase. Integrase, along with protease and a third enzyme, reverse-transcriptase, is one of three key proteins that allow the HIV virus to take over the cellular machinery of the host cell and replicate itself. By producing a more accurate model of integrase, the research allows further searches for new drug molecules that will inhibit the mutant drug resistant forms of this enzyme, as well. The Scripps team was recently awarded government stimulus funding as part of the American Recovery and Reinvestment Act to advance their new project against HIV integrase.

"The volunteers around the world who donate their computer time have helped usher in a potentially new class of drugs that may save lives and increase the quality of life for people living with HIV," said Dr. Joseph Jasinski, Distinguished Engineer and Program Director of IBM’s Healthcare and Lifesciences Institute. "World Community Grid enables a smarter way to conduct promising research by providing unprecedented computing power to projects that might not be positioned to make a difference in the world without access to a free supercomputer."

The FightAIDS@home project will continue to run calculations to further this research against drug-resistant mutant "superbugs" of HIV.

"In the fight against HIV/AIDS it is important to remind people that HIV has not gone away, and that there are many things still to be done," said Joe Solmonese, President of the Human Rights Campaign. "World Community Grid is one way to get involved and makes it easy to contribute to this important research in a meaningful and effective way."

To donate your computer cycle time to humanitarian research covering areas from cancer to more nutritious rice to more efficient energy sources, please visit: www.worldcommunitygrid.org. From this site you can install a small, safe, and secure program that will connect you to the grid. When your computer is idle, data is requested from World Community Grid’s server to perform a computation. Once finished, the result is sent back to the server, prompting it for a new piece of work. It is not necessary to leave a computer on more than usual and we encourage members to continue their normal routines. We can harvest substantial computational power during a normal work day just by taking advantage of the time when someone is on the phone, talking with colleagues, taking a coffee break or doing simple tasks that don't require the full power of the computer.

Other projects running on World Community Grid have produced results including:

  • The Help Defeat Cancer project proved their more accurate technique for identifying cancer and received a $2.5 million grant from NIH to further deploy its system.
  • Discovering Dengue Drugs Together project has identified potential antiviral compounds and is continuing with laboratory work on those.
  • Nutritious Rice for the World project has already returned 12 million transactions and 11,000 years of compute time.

For more information about IBM, please visit ibm.com/smarterplanet/healthcare

For more information about World Community Grid, please visit: www.worldcommunitygrid.org

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...